Consultation Hub

Welcome to the Consultation Hub. This site will help you find, share and participate in consultations that interest you. Below you will find links to the consultations we are currently running.

Alternatively you may search for consultations by keyword, interest or status.  Once finalised, decisions will be published under Closed Consultations.

Open Consultations

  • Public consultation on interim decisions to amend the Poisons Standard - November 2020 ACMS/ACCS meetings

    Scheduling amendments referred to expert advisory committee This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 4-5 November 2020 meetings of the Advisory Committee on... More

    Closes 4 March 2021

  • Mitochondrial Donation in Australia

    The Australian Government Department of Health invites you to share your views on the proposed approach to making mitochondrial donation available in Australia. The Australian Government wants to introduce mitochondrial donation so this lifesaving technology is made available for families impacted... More

    Closes 15 March 2021

  • National Gene Technology Scheme, Consultation Regulation Impact Statement (CRIS)

    In July 2017 the Legislative and Governance Forum on Gene Technology (the Forum) formally commenced the Third Review (Third Review) of the National Gene Technology Scheme (the Scheme). The initial aim of the Review was to assess the operation of the Scheme with respect to its policy... More

    Closes 17 March 2021

  • Public Consultation - Fees and charges proposal 2021-22

    The Therapeutic Goods Administration (TGA) is conducting a public consultation to provide industry and other interested stakeholders with an opportunity to comment on options for the TGA’s proposed fees and charges for the 2021-22 financial year. Specifically, we are seeking feedback on the... More

    Closes 17 March 2021

  • Repurposing of Prescription Medicines

    Repurposing is the process of identifying new uses (or ‘indications’) for medicines. In some cases, prescription medicines may have been used ‘off-label’ for many years to treat conditions that they do not have formal regulatory approval (i.e. are not registered) for. Whilst this may... More

    Closes 23 March 2021

Forthcoming Consultations

Closed Consultations

We Asked, You Said, We Did

Here are some of the issues we have consulted on and their outcomes. See all outcomes

We asked

Public consultation on the Delegate’s interim decision on nicotine scheduling was held between 23 September and 12 November. The interim decision and public consultation relate to a delegate-initiated proposal referred to the June 2020 meeting of the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACMS-ACCS #25).

You said

We received 2385 submissions in response to the public consultation, including seven submissions that were received offline. Respondents provided feedback on the proposed changes to the Poisons Standard. We appreciate all of the feedback that we received.

We did

The Delegate considered all submissions prior to making the final decision on nicotine scheduling. The final decision was published on 21 December 2020 on the TGA website.

We asked

We asked for your feedback on the new ARPANSA Standard for Limiting Exposure to Radiofrequency Fields – 100 KHz to 300 GHz (RPS S-1) because we want to make sure that the standard is fit for purpose and provides clear guidance to industries and regulators to ensure the safety of Australian workers and the general public including people of all ages and health status.

You said

We received 61 submissions from a range of stakeholders, including health authorities, scientists, academic bodies and members of the general public. There were a range of technical comments, questions, and suggestions, as well as comments from members of the public expressing concern about the certainty of the science underpinning the exposure limits.

We did

We have reviewed all submissions and made some amendments, primarily to clarify technical aspects of the Standard. The revised Standard and our responses to individual consultation comments will now undergo formal approvals prior to publication.  

The new Standard will be published on the ARPANSA website in the first quarter of 2021.

We asked

Public consultation on the Delegate’s interim decisions, in relation to scheduling proposals referred to the June 2020 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS), was held between 9 September 2020 and 13 October 2020.

You said

We received 41 submissions in response to the consultation. Respondents provided feedback on the proposed changes to the Poisons Standard. We appreciate all of the feedback we received.

We did

The Delegate considered all submissions in making the final decision on these proposals.

Final decisions regarding oxymetazoline, eletriptan, clotrimazole, sildenafil, ibuprofen and cumyl-pegaclone were published on 25 November 2020.

The final decision for cannabidiol (private application and delegate initiated) was published on 15 December 2020.